HB-EGF plays an indispensable role in suppression of cell proliferation in mouse valvulogenesis. However, ligands of the EGF receptor (EGFR/ErbB1), including HB-EGF, are generally considered as growth-promoting factors, as shown in cancers.
In valvulogenesis, opposing signals generated by different combinations of ErbB-dimers elaborately regulate cell proliferation, in which proteolytically released intracellular domain of ErbB4 activated by HB-EGF is required to suppress proliferation.
Introduction
The ErbB system, comprising epidermal growth factor (EGF) family members and ErbB receptor tyrosine kinases (RTKs), is fundamental in cell proliferation, differentiation, migration, and survival. In mammals, the EGF-ErbB system consists of four receptors: EGF receptor (EGFR)/ErbB1, ErbB2, ErbB3 and ErbB4. It also includes multiple EGF family ligands including EGF, transforming growth factor-alpha (TGF-α), amphiregulin (ARG), heparin-binding EGF-like growth factor (HB-EGF), betacellulin (BTC), epiregulin (ERG), epigen (EPG), and neuregulin (NRG) 1-4. Although EGF family ligands share a conserved receptor-binding motif, and soluble forms are usually produced from membrane-anchored precursors (Harris et al., 2003) , EGF family members bind to the various ErbB receptors with differing degrees of preference (Riese and Stern, 1998) . Moreover, in addition to the different ligand specificities and downstream signalling molecules of ErbB receptors, they form homo-or hetero-dimers in various combinations (Olayioye et al., 2000) . Thus, the vast number of ligand and receptor combinations provides redundancy and robustness in the EGF-ErbB system, which makes it possible for the bioactivities exerted by the system to be finely tuned.
The complexity of the EGF-ErbB system implies that different combinations of EGF family ligands and ErbB RTKs achieve a range of cellular behaviours in vivo. However, the physiological significance of such diversity in the intracellular signals generated by the EGF-ErbB system remains to be elucidated. Moreover, there is little information about how such diverse signals are precisely regulated in vivo, and which EGF ligand-ErbB RTK and ErbB dimer combinations specifically function in certain physiological processes. In this study, we aimed to resolve these issues.
HB-EGF binds to ErbB1 and ErbB4 (Higashiyama et al., 1991; Elenius et al., 1997; Raab and Klagsbrun, 1997) . Analyses of HB-EGF null mice have revealed that HB-EGF plays pivotal roles in several physiological and pathological processes (Mekada and Iwamoto, 2008) . Similar to other ErbB1 ligands, because HB-EGF is a potent mitogen that has been implicated in cancer progression and malignancy, it is generally known as a growth-promoting factor. However, in developmental and physiological processes, HB-EGF is not characterised as a growth-promoting factor but rather acts as a growth-inhibiting or migration-promoting factor (Mekada and Iwamoto, 2008) . Cardiac valve development (valvulogenesis) is an example of a process in which HB-EGF functions as a growth-inhibiting factor (Iwamoto and Mekada, 2006) .
Mouse valvulogenesis occurs in two consecutive steps: cardiac cushion formation and valve remodelling (Schroeder et al., 2003; Armstrong and Bischoff, 2004) . The cardiac cushion is the primordial tissue of cardiac valves, and the cushion formation stage is accompanied by endothelial-to-mesenchymal transition. In mice, this stage is completed by embryonic day (E) 12.5 (Lakkis and Epstein, 1998) and is followed by remodelling of the cushions to form thin valve leaflets. Although much is known about the signalling pathways involved in cushion formation, the molecular mechanisms underlying valve remodelling are still poorly understood. HB-EGF is expressed and functions during the remodelling process (Iwamoto et al., 2010) . Several HB-EGF-deficient mouse lines show valve abnormalities, indicating that HB-EGF is critical for normal valvulogenesis (Iwamoto et al., 2003; Jackson et al., 2003; Yamazaki et al., 2003; Iwamoto and Mekada, 2006; Iwamoto et al., 2010) . Such mutant mice have enlarged cardiac valves due to hyperproliferation of mesenchymal cells. These studies indicate that the soluble form of HB-EGF, which is secreted from endocardial cells, functions as a 'growth-inhibiting' factor for mesenchymal cells. In addition, they suggest that signals promoting cell proliferation exist in parallel with the HB-EGF-mediated inhibitory cascade. However, the precise molecular mechanism controlling such mesenchymal cell proliferation is still unclear.
To address these issues, we performed in vivo experiments using several mutant mouse lines and ex vivo experiments using cardiac cushion explants. The ex vivo experimental culture system recapitulates in vivo phenomena and has shown a functional relationship between HB-EGF and mesenchymal cell proliferation (Iwamoto et al., 2010) . In the present study, we demonstrate the regulatory mechanism for mouse valvulogenesis, in which ErbB RTKs finely regulate mesenchymal cell proliferation in a dual mode via dimerization with different partners: ErbB1 and ErbB4 form a heterodimer receptor for HB-EGF, resulting in growth inhibition, whereas homodimerization of ErbB1 produces a receptor for a certain ErbB1 ligand(s), leading to growth promotion. Moreover, in the former inhibitory signalling, proteolytic processing of ErbB4 is required to release the intracellular domain (ICD) of ErbB4.
These results provide evidence of a novel and elaborate mechanism for the regulation of cell proliferation by specific ErbB dimer combinations in vivo.
Results

ErbB1 is involved in HB-EGF-mediated suppression of valve mesenchymal cell proliferation, as well as ErbB1 ligand-mediated up-regulation of proliferation in the absence of HB-EGF
To investigate the molecular mechanism governing HB-EGF-associated regulation of cell proliferation in valvulogenesis, we performed ex vivo experiments using cardiac cushion explants (Iwamoto et al., 2010) . In this culture system, a cushion explant from an E10.5 embryonic heart was placed on a type I collagen gel containing hyaluronic acid (HA-Col) ( Fig. 1A) . Endocardial cells derived from the endocardium of the cushion explants (ON-gel cells) proliferated and spread on the surface of the HA-Col, while some endocardial cells differentiated to mesenchymal cells that invaded into the HA-Col and proliferated (IN-gel cells) . Under this culture condition, IN-gel cells from HB-EGF knockout (KO) (HB del/del ) explants proliferated much more than those from wild-type (WT) explants, whereas ON-gel cells from WT and HB del/del cushions proliferated at comparable levels ( Fig. 1B,C) . Therefore, this ex vivo experimental system reproduced in vivo data and showed a functional relationship between HB-EGF and mesenchymal cell proliferation (Iwamoto et al., 2010) . Up-regulation of the mesenchymal cell proliferation of HB del/del explants suggests that HB-EGF functions as a 'growth-inhibiting' factor for mesenchymal cells, and that an unknown signal(s) promoting cell proliferation exists in parallel with the HB-EGF-mediated inhibitory cascade. Thus, we investigated which receptors transmit each signal in parallel by first focusing on ErbB1. ErbB1 is thought to be involved in the inhibitory signals induced by HB-EGF, because ERBB1 null mice develop cardiac valve enlargement as observed in HBEGF null mice (Chen et al., 2000; Jackson et al., 2003) .
First, we examined ZD1839, a chemical inhibitor of ErbB1 (Fig. 1B,C) . ZD1839 up-regulated WT cell proliferation as observed previously (Iwamoto et al., 2010) . Moreover, surprisingly, ZD1839 down-regulated hyper-proliferation of HB del/del cells. These results strongly suggest that ErbB1 activity is required not only for HB-EGF-mediated suppression of WT cell proliferation, but also for promotion of increased proliferation in HB del/del cells.
To confirm the above possibility in vivo, we used a hypomorphic ErbB1 mutant, waved-2 (Luetteke et al., 1994) , and tested for a genetic interaction between HBEGF and ERBB1. In waved-2 mice, the kinase activity of ErbB1 is decreased to <10% of that of WT ErbB1 because of a point mutation in the kinase domain. Although waved-2 single mutant embryos (+/+; wa2/wa2) showed a weak but significant valve-enlarged phenotype, the abnormalities in HB del/del and waved-2 double mutant embryos (d/d; wa2/wa2) were significantly weaker than those of HB del/del single mutants (d/d; +/+) (Fig. 2) . These results indicate that ErbB1 is also required to promote the increased proliferation of HB del/del cells. Immunohistochemistry for phospho-ErbB1 showed that the phosphorylation rate of ErbB1 was comparable between WT and HB del/del valves (Fig. S1 ). This finding suggests that, even in the condition without HB-EGF, a certain ligand(s) of ErbB1 still activates ErbB1 in mesenchymal cells of developing valves. Taken together, these results indicate that ErbB1 functions in both HB-EGF-mediated inhibition of mesenchymal cell proliferation and promotion of hyperproliferation in HB-EGF-lacking cells.
ErbB4 is involved in HB-EGF-mediated suppression of valve mesenchymal cell proliferation
Regarding the mechanism of ErbB1 signalling in both inhibition and promotion of cell proliferation, we hypothesised that ErbB1 may function by forming a dimer with different ErbB partners to achieve each function. To examine this possibility, we checked the expression of each ErbB receptor mRNA in explanted cells. RT-PCR analysis showed expression of ErbB1 and ErbB4 but little or no expression of ErbB2 and ErbB3 in valve cells (Fig. S2A ). This result suggests that ErbB1 may function by forming a dimer with ErbB1 itself (ErbB1/ErbB1 homodimer) and/or with ErbB4 Consistent with their low endogenous expression, dn-ErbB2 and dn-ErbB3 had little effect on mesenchymal cell proliferation. Conversely, dn-ErbB4 increased cell proliferation by inhibiting HB-EGF-mediated suppression of WT mesenchymal cell proliferation, but not hyperproliferation of HB del/del cells (Fig. 3C,D) . These results strongly suggest the specific involvement of ErbB4 in the HB-EGF-mediated inhibitory process. The dn-ErbB4 used here was a deletion mutant lacking the cytoplasmic domain ( Fig. 3A) . Thus, there was the possibility that dn-ErbB4 depletes HB-EGF in the culture system, and the effect of the dominate-negative mutant did not represent the supposed dominant-negative effect of ErbB4. However, addition of excess amounts of recombinant HB-EGF protein did not alter the effects of dn-ErbB4 ( Fig. S3 ), ruling out the possibility of HB-EGF depletion by dn-ErbB4. Taken together, these results strongly suggest that activation of the heterodimer consisting of ErbB1 and ErbB4 by HB-EGF suppresses cell proliferation, whereas activation of the ErbB1 homodimer by ErbB1 ligands promotes cell proliferation.
Up-regulation of valve mesenchymal cell proliferation in ErbB4 KO mice
To investigate whether ErbB4 regulates growth inhibition during valvulogenesis in vivo, we analysed the valve phenotype of ERBB4-KO (ERBB4 -/-) mice and examined the proliferation of mesenchymal cells in ex vivo cultures. Because of the early embryonic lethality in ERBB4 -/mice before cushion formation (Gassmann et al., 1995) , which is due to a defect in heart muscle trabeculation, we analysed a mutant mouse line rescued from early embryonic lethality by reintroduction of human ErbB4 (HER4) in cardiomyocytes (Tidcombe et al., 2003) . Because the HER4 cDNA is under the control of the cardiac-specific α-myosin heavy chain (MHC) promoter, these mice express HER4 specifically in cardiomyocytes and not in any other cell type. Thus, the heart develops normally and these mice are born, reach adulthood, and are fertile (Tidcombe et al., 2003) . Although the degree of abnormality was relatively milder, enlargement of the valves in heart-rescued ERBB4 -/-(hr-ERBB4 -/-) newborns was phenotypically similar to that in HB del/del mice (Fig. S4 ). The mesenchymal cells of explants from hr-ERBB4 -/valves showed an approximately 2-fold higher proliferation rate compared with those from WT and hr-ERBB4 +/mice with statistical significance (Fig. 4) . These results indicate that ErbB4 functions in HB-EGF-induced inhibition of mesenchymal cell proliferation in developing valves.
A cleavable JM-a isoform of ErbB4 functions in the suppression of valve mesenchymal cell proliferation
Unlike other ErbB family RTKs, ErbB4 consists of alternatively spliced variants.
Among them, ErbB4 is classified as JM-a or JM-b, if it is with or without a cleavage site by ADAM (a disintegrin and metalloproteinase) 17 in the juxtamembrane domain, respectively (Carpenter, 2003; Veikkolainen et al., 2011) . When activated by ligand binding, the ectodomain of the JM-a type is proteolytically cleaved by ADAM17, generating the membrane-associated C-terminal fragment of ErbB4 (ErbB4-CTF). This cleavage is followed by intramembrane proteolysis by presenilin-1 (PS1), resulting in the translocation of the soluble intracellular domain of ErbB4 (ErbB4-ICD) into the nucleus (Lee et al., 2002; Medina and Dotti, 2002) . The ICD then activates or inhibits the expression of several genes (Veikkolainen et al., 2011) . Conversely, the JM-b type is uncleavable because of a difference in the amino acid sequence corresponding to the juxtamembrane domain, which is recognised by ADAM17. Thus, similar to other ErbB RTKs, the JM-b type activates canonical signalling cascades (Veikkolainen et al.,
2011).
To reveal which ErbB4 isoform (JM-a or JM-b) dimerizes with ErbB1 to inhibit cell proliferation, we examined the expression of these isoforms at the mRNA level. RT-PCR analysis using specific primer sets for the mRNA for each isoform of Uncleavable JM-b significantly increased the proliferation of WT cells, but did not affect hyperproliferation of HB del/del cells (Fig. 6 ). Taken together, these results indicate that JM-a type ErbB4 functions in this process, and suggest that the release of the ErbB4 ICD is required for the HB-EGF-mediated suppression of cell proliferation.
In the present study, we propose a model in which dual ErbB signalling with opposing actions is involved in the regulation of mesenchymal cell proliferation. In this model: 1) activation of the heterodimer of ErbB1 and ErbB4 by HB-EGF suppresses cell proliferation, whereas 2) activation of the homodimer of ErbB1 by a certain ErbB1 ligand(s) promotes cell proliferation (Fig. 7) . The EGF-ErbB system appears to be subject to complex regulation, producing a range of cellular behaviours in vivo; however, the combinations of EGF ligands and ErbB receptors, and the patterns of ErbB dimerization, that achieve different physiological outcomes have been largely unknown. Only a limited number of studies have investigated these issues. For example, previous studies have demonstrated that HB-EGF contributes to mouse heart muscle homeostasis (Iwamoto et al., 2003) and trans-retinoic acid-induced skin hyperplasia Our results indicate that HB-EGF binds to and activates the heterodimer of ErbB1/ErbB4 in mouse valvulogenesis, and that a certain ErbB1-ligand(s) binds to and activates the homodimer of ErbB1. HB-EGF binds to both ErbB1 and ErbB4. However, why HB-EGF selectively activates the ErbB1/ErbB4 heterodimer and does not activate the ErbB1/ErbB1 homodimer in valvulogenesis is unclear. A key factor underlying this selectivity may be the interaction of HB-EGF with heparan sulfate proteoglycans (HSPGs) through the heparin-binding domain of HB-EGF. The interaction between HB-EGF and HSPGs is essential for normal valvulogenesis, as shown in a mutant knock-in mouse expressing a truncated form of HB-EGF that lacks the heparin-binding domain (HB Δ hb/ Δ hb ) (Iwamoto et al., 2010) . It has also been suggested that, in blastocyst implantation, HB-EGF interacts with ErbB4 via HSPGs on the blastocyst cell surface (Paria et al., 1999) . Moreover, HSPG-type CD44 is reported to recruit HB-EGF and ErbB4 during remodelling of female reproductive organs (Yu et al., 2002) . Based on these findings, we presume that the interaction with HSPGs on the mesenchymal cell surface recruits HB-EGF to the ErbB1/ErbB4 heterodimer specifically, but not to the ErbB1/ErbB1 homodimer.
We found that the ErbB1 homodimer contributes to mesenchymal cell proliferation in developing valves. However, the identity of the ErbB1 ligand(s) that activates the ErbB1 homodimer in the mesenchymal cells, leading to the promotion of cell proliferation, is unknown. Based on our proposed requirement for an interaction between HB-EGF and HSPGs for growth inhibition by the ErbB1/ErbB4 heterodimer, among all ErbB1 ligands (HB-EGF, EGF, TGF-α, ARG, ERG, BTC, and EPG), the ligands with a heparin-binding activity, such as ARG and HB-EGF, may be excluded as candidates for the ErbB1-ligand(s). Moreover, expression of EGF, ARG, ERG, and HB-EGF was detectable by RT-PCR in the cultured cells of WT explants (R. Iwamoto, unpublished observation). Thus, taken together, these data suggest that EGF and ERG may be potential ligands of the ErbB1 homodimer. In addition to HB-EGF, single KO (Sierro et al., 2007; Yu et al., 2011) . To understand the entire molecular mechanism governing regulation of cell proliferation in valvulogenesis, it will be important to study the molecular relationship between the ErbB and BMP signalling pathways.
We found that the cleavable JM-a type ErbB4 isoform functions as a receptor for HB-EGF in the suppression of mesenchymal cell proliferation, leading to the possibility of direct nuclear signalling mediated by the ICD of ErbB4 (Fig. 7) . In this study, forced expression of cleavable JM-a or ICD rescued ErbB4 -/cells from hyperproliferation, and expression of uncleavable JM-b up-regulated WT cell proliferation by inhibiting HB-EGF-mediated suppression of cell proliferation.
Therefore, these results indicate that ErbB4 cleavage is essential, and that the ErbB4 ICD is necessary and sufficient for the inhibitory signalling in valve mesenchymal cells.
Several lines of in vitro evidence indicate that the biological functions of JM-a and JM-b are different (Carpenter, 2003; Veikkolainen et al., 2011) . However, the physiological functions of each isoform in vivo are unclear. Thus far, only one report has directly indicated a physiological function of JM-a, demonstrating a role in astrocyte differentiation during neural development (Sardi et al., 2006) . Thus, our study adds valvulogenesis as a novel physiological process in which JM-a physiologically functions in vivo. The ErbB4-ICD form, which is an artificially truncated transmembrane domain, has been thought to be constitutively active (Linggi et al., 2006; Muraoka-Cook et al., 2009 ). However, the rescue activity of the ICD in ERBB4 -/explants was weaker than that of the full-length JM-a form. A similar result was obtained in our experiment with HB del/del explants. These results suggest that, for ErbB4-ICD to fully function in nuclear signalling, the ICD must be synthesised, presented on the cell surface as the full-length transmembrane JM-a type of ErbB4, and then sequentially cleaved on the cell surface and released into the cytoplasm.
ADAM17 (also known as tumour necrosis factor-α converting enzyme; TACE) is a member of the ADAM family metalloproteases (Scheller et al., 2011) and is suggested to be a major sheddase of HB-EGF during valvulogenesis because ADAM17 KO valves phenocopy HBEGF KO valves (Jackson et al., 2003; Wilson et al., 2013) .
Similar to HB-EGF, ectodomain shedding of JM-a type ErbB4 is also thought to be mediated by ADAM17 (Rio et al., 2000; Veikkolainen et al., 2011) . Shedding of ErbB4 by ADAM17 is thought to be required before proceeding with intramembrane proteolysis by PS1, which results in releasing the ErbB4 ICD into the cytoplasm (Ni et al., 2001; Veikkolainen et al., 2011) . Therefore, in the inhibitory process mediated by the HB-EGF-ErbB4 axis, ADAM17 may act as a sheddase with dual functions to shed HB-EGF in endocardial cells and ErbB4 in mesenchymal cells. The molecular mechanism governing the regulation of this protease during valve remodelling processes should be investigated further in future studies.
HB-EGF plays important roles in cancer cell proliferation, malignancy, metastatic potential, and chemotherapy resistance (Miyamoto et al., 2006) . In particular, HB-EGF expression is increased in advanced ovarian cancer compared with normal ovarian tissue (Miyamoto et al., 2004) and associated with poor clinical outcomes (Tanaka et al., 2005) . HB-EGF is not only expressed in cancer cells, but also in the cancer-surrounding stroma, which is involved in tumour progression (Murata et al., 2011) . Thus, HB-EGF is recognised as a possible target for cancer therapy. An anti-HB-EGF antibody (Miyamoto et al., 2011) and CRM197 (a nontoxic mutant form of diphtheria toxin that neutralises HB-EGF activity) are undergoing clinical development as anticancer drugs (Nam et al., 2014) . However, such blocking therapies also have potential side effects associated with the inhibition of "physiological" HB-EGF. Interestingly, such physiological processes that promote cell proliferation have not been found so far (Mekada and Iwamoto, 2008; Iwamoto and Mekada, 2012) .
Conversely, in valvulogenesis, HB-EGF functions as an "inhibitory" factor. This suggests the concept of inhibiting the proliferation of cancer cells expressing HB-EGF by converting the HB-EGF function in proliferation from "promotion" to "suppression". This could be achieved by introducing a key factor or system into the cancer cells, which governs the inhibitory mechanism in mesenchymal cells during valvulogenesis.
The present study provides us with hope that ErbB4 or the pathway downstream of ErbB4 will be a strong candidate for such a key factor. Further study of the regulatory mechanism mediated by the HB-EGF-ErbB4 signalling axis in valvulogenesis may shed light on establishing a novel method for molecular targeted cancer therapy.
Mice
The generation of HBEGF-KO (HB del/del ) mice has been described previously (Iwamoto et al., 2003) . These mice were backcrossed for more than 13 generations onto a C57BL/6J background. Waved-2 mice (Luetteke et al., 1994) were purchased from the Jackson Laboratory. Waved-2 mice with a mixed background of C57BL/6JEi and C3H/HeSnJ when purchased were backcrossed for more than 5 generations onto a C57BL/6J background. To establish double mutant mice of waved-2 and HB del , HB del/+ mice were mated with waved-2 heterozygous (wa2/+) mice. ERBB4-KO (Gassmann et al., 1995) Gassmann (University of Basel). ERBB4 +/-HER4 heart males were crossed with ERBB4 +/-HER4 heart females to generate ERBB4 -/-(null)-, ERBB4 +/--HER4 heart , and WT embryos.
The discovery of a vaginal plug was considered as E0.5. To analyse valve development and ex vivo cultures, timed pregnant females were sacrificed, and embryos at a suitable stage for each analysis as shown below were dissected from the uteri and placed in phosphate-buffered saline (PBS). All mice used in this study were housed in the Animal CYT-1 type ErbB4-ICD (Sundvall et al., 2007) were generated by site-directed mutagenesis via PCR using cDNA encoding full length JM-b CYT-1 type ErbB4 as a template. All generated constructs were cloned into pLVSIN-IRES ZsGreen1 (Clontech) to produce lentiviruses for infection of cushion explant cultures as described below. Preparation and titering of lentiviruses were carried out according to the manufacturer's instructions. ZsGreen1 is an analogue of green fluorescent protein (GFP) and referred to as "GFP" in this study.
Endocardial cushion explant cultures
To examine the proliferation of valve mesenchymal cells in vitro, the original method of endocardial cushion explant culture (Camenisch et al., 2002) was modified as described previously (Iwamoto et al., 2010) . In brief, a cushion explant from an E10.5 embryonic heart was placed on a type I collagen gel (Cellmatrix Type I In experiments using lentivirus expression vectors encoding the cDNAs described above, lentivirus infection was carried out on day 5 after starting the culture, and then the cells were cultured for a further 5 days. To infect both IN-gel and ON-gel cells, 10-20 μl of concentrated virus solution (>1 × 10 9 TU/ml) in Medium 199 was directly infused into the gel beneath the explant via an ultrathin capillary. After a total 10 days in culture, the proliferation of ON-gel and IN-gel cells was measured by immunocytochemistry with a polyclonal antibody against Ki67 (Novocastra) as a mitotic marker. An image of the Ki67-stained explant was captured by the confocal laser scanning microscope system and analysed with Adobe Photoshop software. In these cDNA introduction experiments, the total colour of the captured image was automatically converted to clearly distinguish signals of GFP and Ki67 (Fig. 3B) . All data were analysed in a blinded manner.
Histological analysis
Haematoxylin and eosin staining and measurement of valve size were performed as described previously (Iwamoto et al., 2003) . At E18.5 to postnatal day 0, the hearts of embryos or pups were fixed with 4% paraformaldehyde and embedded in optimal cutting temperature compound. For immunohistochemistry to detect phosphorylated ErbB1, serial frozen sections (8 μm) were incubated with an anti-pY1068-ErbB1 rabbit monoclonal antibody (Cell Signaling) using the Duolink II system (Sigma-Aldrich) according to the manufacturer's instructions. For immunohistochemistry to detect total ErbB1, sections were incubated with a biotinylated anti-ErbB1 rabbit polyclonal antibody (Cell Signaling) and then Alexa488-conjugated streptavidin (Molecular Probes).
RT-PCR analysis of ErbB receptors
Total RNA from cushion explant cells (mixture of IN-gel and ON-gel cells after removal of explants) cultured for 10 days was isolated using an RNeasy Micro kit (Qiagen). Total RNA was reverse transcribed using reverse transcriptase ReverTra Ace (TOYOBO).
PCR analysis was performed using ExTaq (TOYOBO) for each gene as follows: , and centrifuged at 20,000 × g for 30 min. The supernatant was collected, mixed with sodium dodecyl sulfate (SDS) gel sample buffer with or without 10% β-mercaptoethanol, and loaded onto 7.5% SDS electrophoresis gels. Separated proteins were electrotransferred onto a polyvinylidene difluoride membrane (Immobilon-P, Millipore). The membrane was blocked in TTBS (10 mM Tris-HCl, pH 7.5, 0.15 M NaCl, 0.05% Tween 20) containing 1% dry skim milk for 1 h, followed by incubation with a mouse anti-myc (9E10) monoclonal antibody (Santa Cruz Biotechnology) at 1 µg/ml in TTBS for 1 h. The membrane was then incubated with a horseradish peroxidase-conjugated secondary antibody (1:3000) for 1 h. Chemiluminescent detection was carried out with the ECL detection system (Pierce) according to the manufacturer's instructions.
Immunostaining
Human HT1080 cells were transiently transfected with lentiviruses containing each construct and then cultured for 72 h in DMEM containing 10% heat-inactivated FCS.
Then, the cells were washed and the medium was replaced with fresh medium without FCS. After overnight culture, the cells were fixed with 4% paraformaldehyde in PBS at room temperature for 15 min, permeabilized with 0.5% Triton X-100 in PBS at room temperature for 15 min, blocked with blocking solution (2% donkey serum, 1% bovine serum albumin, and 0.05% Tween 20 in PBS), and incubated with a mouse anti-myc (9E10) monoclonal antibody (Santa Cruz Biotechnology) at 2 µg/ml in blocking solution at 4°C overnight. The cells were then incubated with Alexa546-conjugated donkey anti-mouse IgG (1:500; Molecular Probes).
Data analysis
All quantitative data are presented as the mean ± SE. Statistical significance was assessed by the two-tailed Student's t-test. A value of p < 0.05 was considered statistically significant.
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